S&Co Inc Amgen Inc Transaction History

S&Co Inc

$1.53 Billion
Q3 2024

A detailed history of S&Co Inc transactions in Amgen Inc stock. As of the latest transaction made, S&Co Inc holds 834 shares of AMGN stock, worth $220,351. This represents 0.02% of its overall portfolio holdings.

Number of Shares

834

Previous 834 -0.0%

Holding current value

$220,351

Previous $260,000 3.08%

% of portfolio

0.02%

Previous 0.02%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$218.65 - $271.46 $182,354 - $226,397	834 New	834 $224,000
Q4 2022 Feb 07, 2023	BUY	$229.03 - $291.01 $191,011 - $242,702	834 New	834 $219,000
Q2 2022 Aug 09, 2022	BUY	$230.71 - $256.74 $922 - $1,026	4 Added 0.48%	834 $202,000
Q1 2022 May 05, 2022	BUY	$219.27 - $242.57 $181,994 - $201,333	830 New	830 $200,000
Q3 2021 Nov 09, 2021	SELL	$212.27 - $248.7 $176,184 - $206,421	-830 Closed	0 $0
Q1 2021 Apr 23, 2021	BUY	$221.91 - $258.6 $184,185 - $214,638	830 New	830 $206,000
Q4 2020 Jan 28, 2021	SELL	$216.38 - $257.67 $179,595 - $213,866	-830 Closed	0 $0
Q3 2020 Dec 11, 2020	BUY	$234.65 - $260.95 $194,759 - $216,588	830 New	830 $211,000
Q1 2020 Apr 28, 2020	SELL	$182.24 - $241.7 $151,259 - $200,611	-830 Closed	0 $0
Q4 2019 Jan 24, 2020	BUY	$189.21 - $243.2 $157,044 - $201,856	830 New	830 $200,000
Q3 2018 Nov 05, 2018	SELL	$185.29 - $208.89 $3.64 Million - $4.1 Million	-19,630 Closed	0 $0
Q2 2018 Jul 27, 2018	SELL	$166.05 - $186.51 $3,819 - $4,289	-23 Reduced 0.12%	19,630 $3.62 Million
Q1 2018 May 02, 2018	BUY	$169.43 - $198.0 $8,979 - $10,494	53 Added 0.27%	19,653 $3.35 Million
Q3 2017 Nov 02, 2017	BUY	$167.29 - $191.0 $3.28 Million - $3.74 Million	19,600	19,600 $3.65 Million

Others Institutions Holding AMGN

# of Institutions

3,121

Shares Held

407M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of S&Co Inc, based on Form 13F filings with the SEC.

News

Stay updated on S&Co Inc with notifications on news.

Account